We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

133 hedge funds and large institutions have $312M invested in Catalyst Pharmaceutical in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $834K | Put options by funds: $272K

40% more capital invested

Capital invested by funds: $222M → $312M (+$89.5M)

14% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 44

0.96% more ownership

Funds ownership: 64.23% → 65.2% (+0.96%)

6% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 17

1% less funds holding

Funds holding: 135 → 133 (-2)

Holders
133
Holders Change
-2
Holders Change %
-1.48%
% of All Funds
2.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
50
Reduced
44
Closed
17
Calls
$834K
Puts
$272K
Net Calls
+$562K
Net Calls Change
+$642K

Top Buyers

1
State Street
State Street
Massachusetts
+$11.2M
2
RA
Royce & Associates
New York
+$3.36M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$3.18M
4
Citigroup
Citigroup
New York
+$2.59M
5
State Board of Administration of Florida Retirement System
State Board of Administration of Florida Retirement System
Florida
+$2.2M

Top Sellers

1
Goldman Sachs
Goldman Sachs
New York
-$7.15M
2
HP
HealthInvest Partners
Sweden
-$5.84M
3
ACM
AIGH Capital Management
Maryland
-$4.51M
4
Man Group
Man Group
United Kingdom
-$2.5M
5
Los Angeles Capital Management
Los Angeles Capital Management
California
-$1.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$46.1M – – –
State Street
2
State Street
Massachusetts
$41.2M +$11.2M +2,820,053 +46%
BlackRock
3
BlackRock
New York
$38.1M +$2.11M +530,489 +7%
Vanguard Group
4
Vanguard Group
Pennsylvania
$25.8M -$734K -184,784 -3%
RA
5
Royce & Associates
New York
$15M +$3.36M +844,521 +35%
Prudential Financial
6
Prudential Financial
New Jersey
$12.7M +$309K +77,842 +3%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$8.14M +$652K +164,171 +10%
Goldman Sachs
8
Goldman Sachs
New York
$6.56M -$7.15M -1,800,597 -56%
LSV Asset Management
9
LSV Asset Management
Illinois
$6.5M -$327K -82,400 -6%
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$5.55M +$1.87M +470,649 +64%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$5.46M +$1.99M +500,706 +73%
Northern Trust
12
Northern Trust
Illinois
$5.41M -$311K -78,168 -6%
Jacobs Levy Equity Management
13
Jacobs Levy Equity Management
New Jersey
$5.25M +$3.18M +801,397 +238%
Charles Schwab
14
Charles Schwab
California
$4.47M -$99.5K -25,033 -3%
Two Sigma Advisers
15
Two Sigma Advisers
New York
$4.13M +$668K +168,200 +23%
N
16
Nuveen
North Carolina
$4.04M -$156K -39,348 -4%
Schroder Investment Management Group
17
Schroder Investment Management Group
United Kingdom
$3.54M -$578K -145,486 -16%
AQR Capital Management
18
AQR Capital Management
Connecticut
$3.34M -$1.07M -269,778 -27%
Citigroup
19
Citigroup
New York
$3.1M +$2.59M +652,727 +3,183%
Russell Investments Group
20
Russell Investments Group
United Kingdom
$3.04M +$852K +214,455 +48%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$2.93M +$39.3K +9,887 +2%
Federated Hermes
22
Federated Hermes
Pennsylvania
$2.89M -$19.8K -4,973 -0.8%
Millennium Management
23
Millennium Management
New York
$2.82M +$695K +174,924 +40%
GC
24
Globeflex Capital
California
$2.81M +$931K +234,284 +62%
Two Sigma Investments
25
Two Sigma Investments
New York
$2.68M +$843K +212,182 +57%
1
2 3 4 5

CPRX Hedge Fund Activity: Q1 2021 in Review

133 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2021, worth a combined $312M — up 40% from $222M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of CPRX and 16 opened new positions — a net loss of 1 holder — while 44 trimmed existing stakes and 50 added.

The largest buyer was State Street, adding an estimated $11.2M. The largest seller was Goldman Sachs, cutting an estimated $7.15M.

  • 133 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2021, down from 135 in Q4 2020.
  • Funds reported $312M of Catalyst Pharmaceutical stock for Q1 2021, up 40% quarter-over-quarter.
  • 16 funds opened new Catalyst Pharmaceutical positions in Q1 2021 and 17 closed out, a net change of -1 holder.
  • The largest Catalyst Pharmaceutical buyer in Q1 2021 was State Street, an estimated $11.2M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2021 was Goldman Sachs, an estimated $7.15M sold.

Based on aggregated 13F filings for Q1 2021.